Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.25
-0.14-2.60%
At close: -
$5.25
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
ITeos Therapeutics Analyst Ratings and Price Targets | NASDAQ:ITOS | Benzinga
ITeos Therapeutics Inc has a consensus price target of $33.17 based on the ratings of 6 analysts. The high is $59 issued by SVB Leerink on May 13, 2022. The low is $15 issued by JP Morgan on March 6, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, JP Morgan, and HC Wainwright & Co. on March 6, 2025, respectively. With an average price target of $26 between Wells Fargo, JP Morgan, and HC Wainwright & Co., there's an implied 395.24% upside for ITeos Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
JP Morgan
HC Wainwright & Co.
JP Morgan
Wedbush
1calculated from analyst ratings
Analyst Ratings for ITeos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/06/2025 | Buy Now | 223.81% | Wells Fargo | Eva Fortea Verdejo19% | $19 → $17 | Maintains | Overweight | Get Alert |
| 03/06/2025 | Buy Now | 185.71% | JP Morgan | Brian Cheng38% | $22 → $15 | Maintains | Overweight | Get Alert |
| 03/06/2025 | Buy Now | 776.19% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 01/16/2025 | Buy Now | 300% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 261.9% | Wells Fargo | Eva Fortea Verdejo19% | $31 → $19 | Maintains | Overweight | Get Alert |
| 12/13/2024 | Buy Now | 300% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 776.19% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 776.19% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 490.48% | Wells Fargo | Eva Fortea Verdejo19% | → $31 | Initiates | → Overweight | Get Alert |
| 08/12/2024 | Buy Now | 357.14% | JP Morgan | Brian Cheng38% | $27 → $24 | Maintains | Overweight | Get Alert |
| 05/13/2024 | Buy Now | 776.19% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $44 → $46 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 414.29% | JP Morgan | Brian Cheng38% | $29 → $27 | Maintains | Overweight | Get Alert |
| 03/07/2024 | Buy Now | 738.1% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $44 → $44 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2023 | Buy Now | 452.38% | JP Morgan | Daniel Wolle9% | $32 → $29 | Maintains | Overweight | Get Alert |
| 10/18/2023 | Buy Now | 528.57% | Wedbush | David Nierengarten61% | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 738.1% | HC Wainwright & Co. | Swayampakula Ramakanth47% | $54 → $44 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 928.57% | HC Wainwright & Co. | Swayampakula Ramakanth47% | → $54 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 509.52% | JP Morgan | Daniel Wolle9% | $34 → $32 | Maintains | Overweight | Get Alert |
| 03/16/2023 | Buy Now | 528.57% | Wedbush | David Nierengarten61% | $45 → $33 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 1023.81% | SVB Leerink | Daina Graybosch43% | $60 → $59 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for ITeos Therapeutics (ITOS) stock?
The latest price target for ITeos Therapeutics (NASDAQ:ITOS) was reported by Wells Fargo on March 6, 2025. The analyst firm set a price target for $17.00 expecting ITOS to rise to within 12 months (a possible 223.81% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
The latest analyst rating for ITeos Therapeutics (NASDAQ:ITOS) was provided by Wells Fargo, and ITeos Therapeutics maintained their overweight rating.
When was the last upgrade for ITeos Therapeutics (ITOS)?
There is no last upgrade for ITeos Therapeutics
When was the last downgrade for ITeos Therapeutics (ITOS)?
There is no last downgrade for ITeos Therapeutics.
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $19.00 to $17.00. The current price ITeos Therapeutics (ITOS) is trading at is $5.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.